Arix Bioscience

Arix Bioscience is a global venture capital firm dedicated to investing in and developing breakthrough biotech companies that leverage cutting-edge advances in life sciences. The firm sources, finances, and builds world-class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies. Arix Bioscience is listed on the Main Market of the London Stock Exchange.

The firm's investment strategy focuses on early-stage and growth-stage companies, primarily in the biotechnology and healthcare sectors. Arix Bioscience collaborates with exceptional entrepreneurs to build companies around game-changing life science innovations. The firm has a diversified portfolio, with investments spanning various therapeutic areas, including oncology, immunology, and rare diseases. Arix Bioscience's geographical focus includes the United Kingdom, United States, Israel, Australia, and several European countries.

Arix Bioscience's portfolio includes companies such as Autolus Therapeutics, a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, and Harpoon Therapeutics, a clinical-stage immunotherapy company developing a novel class of T cell engagers. The firm's approach combines operational and strategic direction with patient capital to drive value in both private and public companies. Arix Bioscience's commitment to medical innovation is evident through its support of companies like OptiKira, which is developing drugs to prevent blindness, and Pharmaxis, which has released positive results from a Phase 1 clinical trial for a LOXL2 inhibitor compound. The firm's investments aim to accelerate the development of important new treatments for patients worldwide.

Arix Bioscience's investment philosophy emphasizes collaboration with exceptional entrepreneurs and provides the capital, expertise, and networks necessary to accelerate their ideas into important new treatments for patients. The firm's operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies. Arix Bioscience's portfolio companies benefit from the firm's extensive network and resources, enabling them to advance their innovative therapies and bring them to market more efficiently. The firm's commitment to medical innovation and patient care drives its investment decisions and strategic partnerships, positioning Arix Bioscience as a leading venture capital firm in the life sciences sector.